AGENUS INC Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
AGENUS INC (AGEN) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 3.05 million shares for the 3-month period ending 2021-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2022-11-08
- AGENUS INC incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2021-09-30 was 3.05M shares.
- AGENUS INC incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2019-03-31 was 17.39M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 9 month |
|---|---|---|
| 2021-09-30 | 3.05M shares 10-Q · filed 2022-11-08 | 8.41M shares 10-Q · filed 2022-11-08 |
| 2019-03-31 | 17.39M shares 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |